Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1

Conditions

Neoplasms 4Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Thymoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Paclitaxel 96Carboplatin 81Bevacizumab 62Gemcitabine 36liposomal doxorubicin 32pembrolizumab 30Topotecan 26olaparib 23Taxes 23niraparib 17Immunoglobulin G 17Disulfides 17Docetaxel 16Cyclophosphamide 16Cisplatin 14Nivolumab 11rucaparib 10durvalumab 10Doxorubicin 9Albumin-Bound Paclitaxel 8sargramostim 7pazopanib 7fludarabine phosphate 7fludarabine 7avelumab 7Magnetic Resonance Spectroscopy 7Ifosfamide 7epacadostat 6Trabectedin 6Sorafenib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Ovarian Neoplasms × MK 2206 × Clear all
NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Merck Sharp & Dohme LLC

Phase 1 Terminated
47 enrolled 12 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT01283035 2016-06-24

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled 7 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡